GEN Exclusives

More »

GEN News Highlights

More »
May 6, 2009

Novotech and ETI Ally to Harness Indian Clinical Research Opportunities

  • Australia-based CRO, Novotech, and Indian CRO, ETI Klinical, are teaming up to help meet the growing international demand for clinical research in India.

    The joint venture aims to cover a wide range of therapeutic areas including oncology, respiratory disorders, infectious diseases, psychiatry, metabolic disorders, devices, and vaccines. The firms will also offer flexible data management capabilities including Oracle Clinical and SAS as well as Novotech’s Clintrial.

    Novotech’s Asian services were launched in 2007. This collaboration helps exploit what Novotech CEO, Alek Safarian, calls huge opportunities in the growing Indian clinical research sector. “We approached Novotech because of its proven reputation in the region, its focus on Australasia, and its global development reach and client network,” adds Karle Group CEO, Mahendra Karle.

    By taking advantage of ETI’s extensive reach across India, the partners say that clients will have access to 92 trial-ready sites with proven recruitment capabilities and compliance, equating to over 5 million patients, 13,000 beds, and 760 investigators with a cumulative experience of 5,000 years.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?